東曜藥業-B(01875.HK)委任肖賁為集團高級財務總監
格隆匯1月31日丨東曜藥業-B(01875.HK)公佈,公司聯席公司祕書及集團財務管理處副總經理姚朝昶已辭任其上述職務,自2022年2月1日起生效。
集團財務管理處高級總監肖賁已接任姚朝昶的財務相關職能,並已獲委任為集團高級財務總監,自2022年2月1日起生效。
集團法務處高級總監陳一帆已獲委任為公司聯席公司祕書,以接替姚朝昶,自2022年2月1日起生效,惟須滿足若干條件,包括公司目前另一名聯席公司祕書呂穎一先生將自陳先生委任生效之日起計獲留任三年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.